Welcome to our dedicated page for Adverum Biotech news (Ticker: ADVM), a resource for investors and traders seeking the latest updates and insights on Adverum Biotech stock.
Adverum Biotechnologies, Inc. reports developments as a clinical-stage biotechnology company focused on intravitreal gene therapy for ocular diseases. Its updates center on ixoberogene soroparvovec, or Ixo-vec, a one-time intravitreal candidate for neovascular, or wet, age-related macular degeneration, including ARTEMIS Phase 3 trial communications and clinical or regulatory disclosures.
Recurring news also includes operating and financial results, inducement equity awards under Nasdaq Listing Rule 5635(c)(4), material agreements, capital-structure matters, shareholder and governance disclosures, and corporate transaction communications.
Adverum Biotechnologies (Nasdaq: ADVM), a clinical-stage company focused on gene therapy for ocular diseases, announced its participation in TD Cowen’s Genetic Medicines & RNA Summit.
Laurent Fischer, M.D., the company's president and CEO, will engage in a fireside chat at the summit on June 21, 2024, at 10:00 a.m. ET.
The event will be webcasted live and accessible via Adverum's website under the Investors section, with a replay available for at least 30 days post-event.
Adverum Biotechnologies announced the appointments of Dr. Rabia Gurses Ozden as Chief Medical Officer and Dr. Szilárd Kiss as a Board Member, effective June 11, 2024. Dr. Ozden, with over 20 years in ophthalmology drug development, transitions from the board to the executive team, bringing her expertise in clinical development and gene therapies. Dr. Kiss, an experienced retina specialist and gene therapy expert, will fill Ozden's vacated board seat. Their contributions are expected to advance Adverum's Ixo-vec gene therapy for wet AMD, particularly through the LUNA trial and pivotal studies.
Adverum Biotechnologies, Inc. (Nasdaq: ADVM) reported Q1 2024 financial results and pipeline highlights, showcasing strong cash position, positive preliminary data from the LUNA trial, and upcoming milestones. The company presented a 26-week interim analysis at ASRS on Ixo-vec for wet AMD, with promising reduction in injections and good tolerability. Financially, the company's cash, cash equivalents, and short-term investments increased to $193.3 million, supporting operations into late 2025.
Adverum Biotechnologies, Inc. (Nasdaq: ADVM) will participate in upcoming investor conferences in May 2024 to showcase its gene therapy for ocular diseases. The company will present at the 2024 RBC Global Healthcare Conference, BofA Securities 2024 Health Care Conference, and H.C. Wainwright 2nd Annual BioConnect Investor Conference. Investors can access the webcast on Adverum's website.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.